Unique ID issued by UMIN | UMIN000026825 |
---|---|
Receipt number | R000030792 |
Scientific Title | Impact of exocrine insufficiency of pancreas and supplementation of pancreatic digestive enzymes on nonalcoholic fatty liver disease (REMOTE study) |
Date of disclosure of the study information | 2017/06/01 |
Last modified on | 2017/04/01 20:16:22 |
Impact of exocrine insufficiency of pancreas and supplementation of pancreatic digestive enzymes on nonalcoholic fatty liver disease (REMOTE study)
Classification and treatment of NAFLD based on pancreatic exocrine function
Impact of exocrine insufficiency of pancreas and supplementation of pancreatic digestive enzymes on nonalcoholic fatty liver disease (REMOTE study)
Classification and treatment of NAFLD based on pancreatic exocrine function
Japan |
Before starting enrollment
Gastroenterology | Hepato-biliary-pancreatic medicine |
Others
NO
The aim of this clinical study is a clarification of clinical usefulness to define a subtype in nonalcoholic fatty liver diseases (NAFLD) based on pancreatic exocrine function. For non-obese NAFLD patients, pancreatic exocrine function and efficacy to supplement pancreatic digestive enzymes are evaluated.
Safety,Efficacy
Ultrasound findings for fatty liver 24 weeks after the enrollment
Shear wave velocity of the liver evoked by acoustic radiation force impulse
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
No treatment
2
Treatment
Medicine |
Evaluation and encouraging in terms of energy-balanced life style and oral administration of pancrelipase (600 mg a day for 24 weeks)
Evaluation and encouraging in terms of energy-balanced life style
Not applicable |
Not applicable |
Male and Female
1) Ultrasound reveals fatty liver as two or more following criteria are fulfilled.
i. Liver/kidney contrast
ii. Vascular blurring in the liver
iii. Deep-attenuation of echo-beam in the liver
2) Shear wave elastography is 1.41 m/sec or faster.
3) A written informed consent is obtained from a patient him/her self.
1) HBV positive
2) HCV positive including a SVR12 case
3) Alcohol consumption more than 20g/day
4) An organic diseases of pancreas or a past History of chronic pancreatitis
5) Allergy against porcine proteins
6) Already taking pancrelipase
7) Taking a medication for diabetes mellitus or HbA1c is 8 or higher
8) Serum triglyceride concentration is 1000 mg/dl or higher
9) Other serious conditions judged to be inadequate by a responsible doctor
60
1st name | |
Middle name | |
Last name | Takeshi Suda |
Uonuma Institute of Community Medicine, Niigata Medical and Dental Hospital
Department of Gastroenterology and Hepatology
4132 Urasa, Minami-Uonuma, Niigata 949-7302, Japan
81-25-777-3200
tspitt@med.niigata-u.ac.jp
1st name | |
Middle name | |
Last name | Takeshi Suda |
Uonuma Institute of Community Medicine, Niigata Medical and Dental Hospital
Department of Gastroenterology and Hepatology
4132 Urasa, Minami-Uonuma, Niigata 949-7302, Japan
81-25-777-3200
tspitt@med.niigata-u.ac.jp
Uonuma Institute of Community Medicine, Niigata Medical and Dental Hospital
Uonuma Institute of Community Medicine, Niigata Medical and Dental Hospital
Self funding
NO
2017 | Year | 06 | Month | 01 | Day |
Unpublished
Preinitiation
2017 | Year | 05 | Month | 01 | Day |
2017 | Year | 06 | Month | 01 | Day |
2017 | Year | 04 | Month | 01 | Day |
2017 | Year | 04 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030792
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |